May 6, 2025
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking placenext week from May 13th to the 17th in New Orleans, is one of the premier international gatherings for the gene and cell therapy community. This year, the Envol Biomedical team is excited to join scientists, innovators, and industry leaders from around the world to share insights, showcase their latest capabilities, and strengthen connections with friends, customers, and colleagues. ASGCT brings together cutting-edge research, technology, and clinical advances — and Envol is proud to play a role in supporting the breakthroughs that will shape the future of medicine.
Envol’s Expanding Capabilities in CNS and Beyond
At ASGCT 2025, the Envol Biomedical team will highlight its expanded expertise in central nervous system (CNS) delivery — an area that has grown significantly over the past year. CEO Jacob McDonald explains:
“We’ve added MRI-guided infusion technology through our collaboration with ClearPoint Neuro, allowing us to perform highly precise CNS dosing in nonhuman primates (NHPs). We’re also advancing our techniques for serial sampling, giving our clients a better look at how their therapies penetrate the CNS over time.”
In addition to CNS work, Envol is expanding its specialized services in ocular and intranasal delivery, responding to growing client demand for precise gene therapy delivery routes. These additions strengthen Envol’s position as a leading NHP research partner for gene and cell therapy companies looking to bring novel therapies to market.
Preparing for GLP: Building Toward New Regulatory Services
Another major milestone on the horizon is Envol’s upcoming Good Laboratory Practice (GLP) compliance — with full GLP services expected to come online by the third quarter of 2025.
“We’re building out our GLP capabilities so we can offer fully compliant studies for our clients working in primates,” says McDonald. “This is a critical step for companies moving into regulatory studies, and we’re excited to support that need with the same expertise and precision we bring to all our projects.”
Watching Industry Shifts and Innovation Trends
Envol’s team won’t just be at ASGCT to showcase their own advancements — they’re also eager to hear what others are seeing across the gene therapy landscape.
“We’ve seen a lot of changes this year, from large companies like Vertex and Roche pulling back funding to growing questions about the reliability of adenovirus vectors,” McDonald notes. “At the same time, we’re seeing exciting new data in gene editing. ASGCT is the place to engage on where the field is heading and how we can all help shape the future.”
The Value of Primate Expertise in Gene Therapy
For companies working in genetic medicine, the right preclinical partner makes all the difference.
“Envol is the primate expert,” says McDonald. “We provide highly technical expertise in surgery, specialized dosing, and regulatory support to help companies advance their gene therapy and gene editing programs. And as a U.S.-based company, we’re focused on providing great value, speed, and service to American innovators.”
Meet the Envol Team at ASGCT 2025
Envol Biomedical invites all ASGCT attendees to stop by their booth to learn more about how their NHP research services can support your next breakthrough. Whether you’re working on CNS delivery, ocular and intranasal administration, or preparing for GLP regulatory studies, the Envol team is ready to help accelerate your success.
The team is also exploring plans for a casual happy hour gathering with members of the lipid nanoparticle (LNP) community — so stay tuned for details if you’d like to join!
We look forward to seeing you in New Orleans at ASGCT 2025. Come by, say hello, and let’s talk about how Envol Biomedical can help bring your gene and cell therapy innovations to life.
Stop by booth #555 to discuss your NHP project needs with the Envol team!